Evozyne vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Evozyne applies generative AI and evolutionary principles to design novel therapeutic proteins; raised $144M total including $81M Series B led by Fidelity and OrbiMed with NVIDIA NVentures participation; 54 employees; Chicago-based.
About
Evozyne is a Chicago-based biotechnology company founded in 2020 by Andrew Ferguson and Rama Ranganathan that uses generative AI to design novel, high-performance proteins for therapeutic and commercial applications. The company occupies a distinctive position at the frontier of AI-driven drug discovery: unlike companies that apply AI to screen existing molecule libraries or predict protein folding (like AlphaFold), Evozyne generates entirely new protein sequences from scratch using its proprietary understanding of evolutionary sequence-function relationships. These de novo proteins are designed with specific functional properties for therapeutic development or industrial applications.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.